NCT03884257View on ClinicalTrials.gov

A Trial to Evaluate the Safety and Efficacy of the Passeo-18 Lux Drug-coated Balloon of Biotronik in the Treatment of the Femoropopliteal Artery Compared to the Medtronic IN.PACT Admiral Drug-coated Balloon.

NAActive, not recruitingINTERVENTIONAL
Enrollment

302

Participants

Timeline

Start Date

February 18, 2020

Primary Completion Date

August 31, 2022

Study Completion Date

September 30, 2026

Conditions
Peripheral Arterial Disease
Interventions
DEVICE

Passeo-18 Lux treatment group

Percutaneous endovascular angioplasty with the Passeo-18 lux

DEVICE

IN.PACT Admiral treatment group

Percutaneous endovascular angioplasty with the IN.PACT Admiral

Trial Locations (14)

1140

Hanusch Hospital, Vienna

2650

UZA, Antwerp

2820

Imelda Hospital, Bonheiden

3100

Clinique Pasteur, Toulouse

3300

R.Z. Heilig Hart, Tienen

3600

Z.O.L., Genk

8036

Medical University of Graz, Graz

8063

Triemlispital Zürich, Zurich

9200

A.Z. Sint-Blasius, Dendermonde

9300

OLV Ziekenhuis Aalst, Aalst

33300

CHU Bordeaux, Bordeaux

75014

Hopital Paris Saint Joseph, Paris

84000

Clinique Rhône Durance, Avignon

CH-1011

Centre Hospitalier Universitaire Vaudois, Lausanne

Sponsors

Lead Sponsor

ID3 Medical
All Listed Sponsors
lead

ID3 Medical

OTHER

NCT03884257 - A Trial to Evaluate the Safety and Efficacy of the Passeo-18 Lux Drug-coated Balloon of Biotronik in the Treatment of the Femoropopliteal Artery Compared to the Medtronic IN.PACT Admiral Drug-coated Balloon. | Biotech Hunter | Biotech Hunter